British Journal of Cancer, Published online: 31 March 2026; doi:10.1038/s41416-026-03408-y Phase 1 study of ceralasertib, an ATR kinase inhibitor, in combination with durvalumab in patients with recurrent or metastatic NSCLC or HNSCC
British Journal of Cancer published a clinical update in Oncology on 31 Mar 2026.
The item focuses on Phase 1 study of ceralasertib, an ATR kinase inhibitor, in combination with durvalumab in patients with recurrent or metastatic NSCLC or HNSCC.
Review the original article for the full source wording and details.